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Abstract
Background: Immunor (IM28), an analog of dehydroepiandrosterone (DHEA), inhibits human
immunodeficiency virus type-1 (HIV-1) by inhibiting reverse transcriptase. We assessed the ability
of IM28 to inhibit the cell-cell fusion mediated by HIV envelope glycoprotein in an in vitro system.
For this purpose, we co-cultured TF228.1.16, a T-cell line expressing stably HIV-1 glycoprotein
envelopes, with an equal number of 293/CD4+, another T cell line expressing CD4, and with the
SupT1 cell line with or without IM28.
Results: In the absence of IM28, TF228.1.16 fused with 293/CD4+, inducing numerous large
syncytia. Syncytia appeared more rapidly when TF228.1.16 was co-cultured with SupT1 cells than
when it was co-cultured with the 293/CD4+ cell line. IM28 (1.6 – 45 µg/ml) completely inhibits cell-
cell fusion. IM28 also prevented the development of new syncytia in infected cells and protected
naive SupT1 cells from HIV-1 infection. Evaluation of 50% inhibitory dose (IC50) of IM28 revealed
a decrease in HIV-1 replication with an IC50 of 22 mM and 50% cytotoxicity dose (CC50) as
determined on MT2 cells was 75 mM giving a selectivity index of 3.4
Conclusions: These findings suggest that IM28 exerts an inhibitory action on the env proteins that
mediate cell-cell fusion between infected and healthy cells. They also suggest that IM28 interferes
with biochemical processes to stop the progression of existing syncytia. This property may lead to
the development of a new class of therapeutic drug.
Background
The human immunodeficiency virus type-1 (HIV-1) enve-
lope glycoprotein is composed of two subunits: a surface
glycoprotein (gp120) and a trans-membrane glycoprotein
(gp41). These two subunits interact with each other in a
non covalent manner. Gp120 is critical for attachment to
host cell CD4 receptors, whereas gp41 contains the fusion
sequence. HIV and simian immunodeficiency virus (SIV)
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require a co-receptor in addition to CD4 for entry into
cells. Primary HIV can use a broad range of co-receptor
molecules, including CCR1, CCR2b, CCR3, CCR4 and
CXCR4 [1-3]. However, expression of a co-receptor
together with CD4 on some cell types does not confer sus-
ceptibility to infection [1]. Not all human cell types that
express an appropriate co-receptor support virus replica-
tion, indicating that other factors that affect viral tropism
are present. HIV-1 viral entry is inhibited in the presence
of the ligands to these chemokine receptors. RANTES,
MIP-1α and MIP-1β, all of which are ligands for CCR5,
inhibit macrophage-tropic isolates, whereas SDF-1, the
specific ligand for CXCR4, inhibits entry by T-cell-tropic
isolates [4-6]. The ability of HIV-1 envelope glycoproteins
to induce cell-cell fusion is an interesting property
because molecules that inhibit the fusion process are pos-
sible antiviral drugs and may lead to the identification of
important functional regions either on the viral glycopro-
tein or on cell membranes. A hydrophobic, 25-amino
acid, conserved segment located at the N-terminus of
gp41 and gp120/41 has been shown to be involved in the
fusion reaction between the viral envelope and the host
cell plasma membrane [7,8]. There is evidence suggesting
that this sequence is also involved in the cytopathic proc-
ess underlying HIV-1 infection of target cells [9,10]. Expo-
sure of this hydrophobic peptide to the aqueous
environment in the vicinity of the target cell initially
depends on gp120/41 function [11]. This protein is acti-
vated after interacting with primary receptor CD4. This
activation requires the presence of human co-factors
[12,13]. According to this model, further interaction of
the fusion peptide to bind membrane lipid with the cell
membrane depends mainly on the ability of the peptide
to bind membrane lipid components. Hence, drugs that
are able to interfere with membrane proteins became rel-
evant for the therapy of HIV, even though it is still impor-
tant to inhibit virus replication. We have previously
shown that IM28 can inhibit HIV-1 reverse transcriptase
activity [14]. Here, we assessed its capacity to inhibit the
fusion of HIV-1-infected cells to naive cells. We found that
IM28 was able to inhibit cell-cell fusion in an in vitro sys-
tem. We showed that IM28 significantly blocks HIV-1
glycoprotein-mediated cell-cell fusion.
Results
We determined the concentrations of various drugs
required to inhibit and to partially inhibit the fusion of
TF228.1.16 and 293/CD4+ (Table 1). All these drugs
decreased the percentage of surface covered by syncytia.
The concentration of IM28 (6.43 µg/ml) that inhibited
the formation of syncytia was similar to that of DXSF 500
000 (3.52 µg/ml) (Table 1). There were no statistical dif-
ferences between the inhibitory concentrations of any of
the drugs tested and IM28. To confirm these observations,
we used SupT1 cells because fusion takes place more rap-
idly in these cells. These cells were mixed with TF22.1.16
cells in the presence or absence of dexamethasone or
IM28 and fusion was examined by light microscopy after
various periods of co-cultivation. In the absence of dex-
amethasone or IM28, TF228.1.16 cells fused with SupT1
cells, forming aggregates (Figure 1a). Infected cells were
spindle-shaped with large syncytia after overnight culture
(Figure b).
In the presence of dexamethasone (Figure 2a) or IM28
(Figure 3), the fusion of TF228.1.16 and SupT1 cells was
completely inhibited in a dose-dependent manner.
Indeed, in the presence of 0.5 µg/ml dexamethasone or
IM28, time of incubation had no effect on syncytia forma-
tion. This concentration of dexamethasone or IM28 did
not result in the lysis of existing syncytia but stopped the
fusion reaction and the appearance of new syncytia (Fig-
ure 3). The time of incubation did not affect the inhibi-
tion of syncytia in the presence of dexamethasone, but did
have an effect for 0.5 µg/ml IM28. In addition, the highest
concentration (> 0.5 µg/ml) of both drugs completely
inhibited syncytia formation. At this concentration of dex-
amethasone, the inhibition of syncytia was accompanied
by cell death bursting (Figure 4), whereas the same con-
centration of IM28 did not lead to the burst (Figure 4).
To further characterize the biological effect of the drug,
the 50% inhibitory dose (IC50) and the cytotoxic dose
(CC50) of IM28 were evaluated and the selectivity index
which is the CC50/IC50 ratio was determined. The
decrease in HIV-1 replication was obtained with an IC50
Table 1: Effect of drugs on fusion of TF228.1.16 cells to 293/CD4+ 
cells
Treatment Effect§
None F F F
IM28 F (0.60) P (1.83) I (6.43)
Dexamethasone F (0.48) P (1.67) I (5.20)
Con A F (0.09) P (0.22) I (0.79)
Heparin F (2.70) P (7.00) I (22.0)
Suramin F (1.57) P (3.90) I (15.0)
Dextran Sulfate 10,000 F (0.02) P (0.06) I (0.20)
Dextran Sulfate 500,000 F (0.37) P (1.15) I (3.52)
§F = 50–60% of the surface is covered by syncytia; P = partial 
inhibition of fusion: < 10% of the surface is covered by syncytia; I = 
inhibition of syncytia formation.
TF228.1.16 cells were mixed with 293/CD4+ cells (1:1 cell ratio) and 
transferred to a 24-well plate (105 cells per well in 200 µl of culture 
medium). TF228.1.16 cells and 293/CD4+ cells were incubated in the 
presence or absence of the drug (the final concentration in µg/ml is 
indicated in parenthesis) for 18 h. Following co-culture, three random 
fields of cells were photographed (not shown) and percentage fusion 
was determined as previously described [10].Virology Journal 2005, 2:9 http://www.virologyj.com/content/2/1/9
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of 22 mM and the CC50 as determined on MT2 cells was
75 mM giving a selectivity index of 3.4.
Discussion
IM28 is a potent new derivative of DHEA that can stop the
replication of HIV-1 by inhibiting its reverse transcriptase
activity [14]. Here, we show that IM28 can also prevent
and inhibit the fusion of infected cells (TF228.1.16 cells)
to naïve cells including 293/CD4+ cells, which are stably
transfected with human CD4 and highly susceptible to
HIV-1 infection, and SupT1 cells [15,16]. The fusion of
293/CD4+ cells with TF228.1.16 cells was completely
inhibited by a lower dose of IM28 than was the fusion of
SupT1 cells with TF228.1.16 cells (data not shown). The
fusion of TF228.1.16 cells to H4CD4+ (CD4 positive glial
cell line) cells obtained by transfection of human neurog-
lioma cells [17] is also inhibited by IM28 (not shown).
Therefore, IM28 and dexamethasone may inhibit cell-cell
fusion and recombination-induced fusion mediated by
the HIV env protein.
Although the precise site at which IM28 acts to inhibit
cell-cell fusion remains unknown, our results suggest that
IM28 fights the HIV-1 virus at a new site. It is possible that
this drug interacts with phospholipase A2 (PLA2), which
plays an important role in the entry of HIV virus in the
host cell [18,19]. Indeed, dexamethasone, a glucocorti-
coid, can inhibit the HIV-1, HIV-2 and SIVmac251 enve-
lope glycoproteins and activate PLA2. PLA2 is activated
when the envelope glycoprotein interacts with CD4. Due
to its local membrane-destabilizing effect, PLA2 may play
an important role in preparing the cell membrane for
fusion with the viral particle. Activated PLA2 hydrolyzes
Photomicrograph of SupT1 cells co-cultivated with TF  228.1.16 cells Figure 1
Photomicrograph of SupT1 cells co-cultivated with TF 
228.1.16 cells. Cell forming syncytia are aggregated (A). In 
the presence of dexamethasone (B) cells are mainly exploded 
vs. in the presence of IM28.
Effect of dexamethasone on fusion of TF228.1.16 cells with  SupT1 cells. Figure 2
Effect of dexamethasone on fusion of TF228.1.16 cells with 
SupT1 cells. TF228.1.16 cells were mixed with SupT11 cells 
(1:1 cell ratio) and transferred to a 24-well plate (105 cells 
per well in 200 ml of cultured medium). After 24 h of co-cul-
ture in the presence or absence of dexamethasone (10 mg/
ml), three random fields of cells were photographed and the 
percentage fusion was determined as described in Table 1.   
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membrane phospholipids in the sn-2 position, producing
arachidonic acid and lysophospholipids [20]. These bio-
chemical events also have downstream effects; the mem-
brane is destabilized locally [21,22], and arachidonic acid
and lysophospholipids are generated. They are potent
detergents and may favor fusion [23]. In addition, arachi-
donic acid is the precursor of eicosanoids, prostanoids,
leukotrienes and lipoxins, which may mediate further
activation [24] and PLA2-induced hydrolysis of ether lip-
ids gives rise to paf-acether [25]. It is possible that the
interaction between gp120 and CD4 specifically modifies
the cell membrane locally, preparing it for fusion. We
hypothesize that the gp120-CD4-co-receptor complex
activates PLA2 through protein kinase C (PKC) and plays
a critical role in the fusion of the membrane phospholip-
ids of the host cells and gp41 before viral entry. Indeed,
the complex formed by CD4 and p56lck acts as the major
receptor for HIV-1, HIV-2 and SIV, delivering intracellular
activating signals. This complex binds to the viral enve-
lope glycoprotein gp120. Following this binding, chem-
okine engagement appears to be required to generate the
fusion active form of the envelope protein. This may
involve the formation of a gp120-CD4-chemokine recep-
tor complex, in which engagement of the chemokine
receptor is dependent on a CD4-induced conformational
change in env gp120 [26-28] as previously defined for the
number of parameters contributing to fusion, i.e., fusion
glycoproteins and the host-cell receptors [29]. However,
Effect of IM28 on fusion of TF228.1.16 cells with SupT1 cells. Figure 3
Effect of IM28 on fusion of TF228.1.16 cells with SupT1 cells. 
TF228.1.16 cells were mixed with SupT11 cells (1:1 cell 
ratio) and transferred to a 24-well plate (105 cells per well in 
200 µl of cultured medium). After 24 h of co-culture in the 
presence or absence of corticosteroids (dexamethasone or 
IM28) (10 µg/ml), three random fields of cells were photo-
graphed and the percentage fusion was determined as 
described in Table 1.
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Effect of IM28 and dexamethasone on SupT1 cells co-cul- tured with TF228.1.16. Figure 4
Effect of IM28 and dexamethasone on SupT1 cells co-cul-
tured with TF228.1.16. Zoom of negative photomicrograph 
of SupT1 cultures co-cultivated with TF 228.1.16 cells (A) in 
the presence of dexamethasone (B) and IM28. Note the evi-
dent syncytia in (A) with an apparent slender shape of 
infected cells. Cells treated with dexamethasone were 
atrophic and sometimes exploded whereas cells incubated 
with IM28 were round.   Virology Journal 2005, 2:9 http://www.virologyj.com/content/2/1/9
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further investigations are required to determine the real
binding site of IM28. It is possible that IM28 acts on virus
replication to inhibit existing syncytia, as previously
reported [14]. Therefore, although the biochemical basis
of this phenomenon remains to be discovered, IM28 pre-
vents and inhibits the cell-cell fusion induced by HIV-1,
giving it additional beneficial effects. Since differential
ability to incorporate or maintain envelope on the virion
might account for the differences in cell-to-cell versus cell-
free infections in primary isolates, further studies with a
more quantitative assay available for determining fusion
inhibition as previously described [33,34] may also
provide us with a greater understanding of the HIV-1
envelope structure and the HIV entry process.
Conclusion
In conclusion, our data show that IM28, a potent new
analog of DHEA, is able to prevent and to inhibit cell-cell
fusion, an important step at the beginning of HIV
infection of naive cells, this drug seems to display the
required properties for an anti-HIV drug.
Methods
Cell lines
Three cell lines were used: TF228.1.16, which is a BJAB cell
line that stably produces functionally active HIV-1 enve-
lope protein (BH-10 clone of HIV-1 LAI) [30]. 293/CD4+
(human embryonic kidney 293 cells which over express
human CD4), obtained through the AIDS Research and
Reference Reagent Program; and SupT1 cells, purchased
from the American Type Culture Collection (Rockville,
MD, USA).
Reagents
DHEA, dextran-sulfate (DXSF), dexamethasone, suramin,
heparin, the mannose-specific lectin concanavalin A
(ConA) and Rowell Park Memorial Institute (RPMI)-1640
medium were purchased from Sigma-Aldrich (St Quentin-
Fallavier, France). Cells were cultured in complete
medium containing L-gltamine, penicillin, streptomycin
and fetal calf serum. All these reagents were purchased
from Invitrogen (Eragny, France). IM28 was produced
from DHEA as specified in its data sheet (INPI 0990847;
Fr2792201; Wo0106666; CRPH, Gabon).
Fusion and syncytia assays
Cultured 293/CD4+ cells in complete medium were har-
vested by trypsinization. These cells (5 × 104) were com-
bined with an equal number of TF228.1.16 cells in a 24-
well plate and incubated overnight at 37°C in a humidi-
fied incubator with 5% carbon dioxide as described by
Moore et al. 1993 [11]. Adherent cells were fixed and
stained with diff-quick (Sigma-Aldrich) and then
observed under a Leitz microscope.
To examine the effect of IM28 on HIV-1 envelope glyco-
protein-mediated fusion, 293/CD4+ cells were mixed
with TF228.1.16 cells in the presence of IM28. As a posi-
tive control for fusion inhibition, cells were incubated in
parallel with dexamethasone, ConA, heparin, suramin
and dextran sulfate 10 000 or 500 000, compounds
known to interfere with mannose residues of envelope
glycoprotein on HIV infectivity and HIV and measles
virus-induced cell fusion [31,32]. The inhibitory activity
of IM28 on fusion of 293/CD4+ cells with TF228.1.16
cells is expressed as a function of concentration and was
compared with the inhibitory activity of the above men-
tioned compounds that interact with the HIV envelope
protein. Fusion was examined by light microscopy after
co-cultivation for 32 h. The percentage fusion is the ratio
of cell surface involved in syncytia to the total cell surface.
Syncytia were defined as giant cells, with diameters more
than four times bigger than those of single cells. Percent-
age fusion was divided into three classes: 56–00% of the
surface covered by syncytial = fusion; partial inhibition of
fusion: < 10% of the surface is covered by syncytial = P;
inhibition of syncytia formation = I.
Statistical analysis
Data were analyzed by one-way analysis of variance
(ANOVA) followed by Dunnett' test. All analyses were
performed using the Graph-Pad Prism® computer pro-
gram. Only P < 0.05 was considered significant.
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